HL7® FHIR® Te Aho o Te Kahu, Cancer Control Agency Implementation Guide
0.1.0 - CI Build

HL7® FHIR® Te Aho o Te Kahu, Cancer Control Agency Implementation Guide, published by Te Aho o Te Kahu, Cancer Control Agency. This guide is not an authorized publication; it is the continuous build for version 0.1.0 built by the FHIR (HL7® FHIR® Standard) CI Build. This version is based on the current content of https://github.com/HL7NZ/cca/ and changes regularly. See the Directory of published versions

## Table of Contents

0 Table of Contents
1 Home
2 Capability Statement
3 Examples
4 Extensions
5 Notes
6 Profiles
7 Terminology
8 Artifacts Summary
8.1 CapabilityStatement
8.2 CancerRegimensLM
8.3 ActivityDefinition
8.4 PlanDefinition
8.5 Dosage
8.6 AdditionalDetails
8.7 Disclaimer
8.8 ESMO-MCBS Score
8.9 Instructions for use
8.10 LocationAdministration
8.11 LocationMedicationCollection
8.12 Off label
8.13 Regimen type
8.14 Regimen under review
8.15 Replaced by
8.16 SupportFactor
8.17 TimingOfDays
8.18 TreatmentSetting
8.19 Administration location
8.20 Cancer type
8.21 ESMO-MCBS Evaluation Form
8.22 Medication collection location
8.23 Medication dose administration frequency
8.24 Medication dose unit
8.25 PlanDefinition additional status
8.26 Possible values for Support Factors
8.27 Regimen type code
8.28 Route
8.29 Support Factors
8.30 Treatment setting
8.31 ESMO-MCBS Evaluation Form
8.32 PlanDefinition additional status
8.33 Regimen type code
8.34 Treatment setting
8.35 ActCabergoline
8.36 ActTragacanth
8.37 Colorectal Adjuvant FOLFOX (a7)
8.38 GU PROS Castration resistant Metastatic - abiraterone and dexamethasone
8.39 GYN END Adjuvant - cISplatin chemoradiation followed by cARBOplatin and PACLItaxel
8.40 LUNG NSCLC Metastatic - alectinib
8.41 LUNG NSCLC NON-Metastatic - alectinib
8.42 SuperceededPlan